Invasive fungal disease (IFD) causes significant morbidity and mortality among children undergoing allo-SCT. In this prospective pilot study, we analyze voriconazole as primary antifungal prophylaxis. From October 2004 to July 2010, 56 children o18 years of age were enrolled in this study. Patients received voriconazole doses of 5 mg/ kg per 12 h (n ¼ 23) or 7 mg/kg per 12 h (n ¼ 33), with a limiting dose of 200 mg/12 h, from day À1 to day þ 75 or later in patients with active acute GVHD. Patients were followed up for IFD for 6 months. In this series, 37 (66.1%) patients successfully completed treatment (85.7% during neutropenic period) without empirical or preemptive antifungal therapy, adverse effects or IFD. Nine (16.1%) children needed preemptive (n ¼ 2) or empirical (n ¼ 7) antifungal therapy, and one (1.8%) of them developed a fatal probable IFD during the study period. A total of 10 (17.8%) children developed adverse effects related to voriconazole prophylaxis, leading to definitive withdrawal on median day 26.5 (in 7 patients after granulocytic recovery). The most frequent adverse effect was persistent elevation of hepatic enzymes in seven (12.5%) children. There were no differences between doses of 5 and 7 mg/kg per 12 h. Our results suggest that voriconazole can be safely used as primary antifungal prophylaxis in children undergoing allo-SCT.
Introduction
Invasive fungal disease (IFD) is currently one of the main causes of infection-related morbidity and mortality in adults and children undergoing allo-SCT. 1, 2 Despite changes in epidemiology, the global incidence of proven or probable mold and yeast infection in adults and children is 413% and has a high mortality rate. [3] [4] [5] Several factors are involved in the incidence and dismal prognosis of this serious complication, including prolonged severe neutropenia, disruption of skin and mucosal defensive barriers, immunosuppression related to a conditioning regimen and acute GVHS (aGVHD) prophylaxis or treatment. 6 Moreover, the increasing number of allo-SCTs from unrelated donors; the use of alternative stem cell sources, such as umbilical cord blood, especially in children with prolonged severe neutropenia; and a higher incidence of acute and chronic GVHD, has led to an increase in IFD cases. 7 The diagnosis of IFD is often difficult, especially in children, because of the controversial value of the tests that are currently available, such as the serum Aspergillus galactomannan Ag (AGA), 8 ,9 the 1-3 b-D glucan test 10 and fungal PCR studies. 11 Thus, diagnosis of IFD is frequently made when the fungal burden is high, which limits the efficacy of antifungal therapy. Consequently, many attempts have been made to reduce the incidence and mortality of IFD using empirical or preemptive therapy. 12, 13 Despite the lack of prospective clinical trials comparing different approaches, primary antifungal prophylaxis is widely used in most of the centers for high-risk patients. The prophylactic use of fluconazole has been shown to reduce the incidence of invasive candidiasis and improve survival; 14 however, this agent is not active against the filamentous fungi, Aspergillus, and has therefore led to an increase in the frequency of invasive aspergillosis with extremely high mortality. 2, 3, 15 The introduction of new and safe antifungal agents has lead to the design of prophylactic prospective controlled trials, [16] [17] [18] but most published studies include few if any pediatric patients. 19, 20 For children who undergo hematopoietic SCT, alternate-day micafungin antifungal prophylaxis has been recently licensed in Europe and Japan. 21 A series of prophylaxis with liposomal amphotericin B (L-AmB) 22 has also been recently published. Voriconazole has broad-spectrum activity against fungal infection, is effective against candidemia, Scedosporium spp. and Fusarium spp., and has been approved for first-line treatment of invasive aspergillosis. However, whether voriconazole primary prophylaxis is able to prevent IFD in a pediatric population has never been explored. Therefore, we have conducted a prospective, pilot study in high-risk pediatric patients undergoing allo-SCT to evaluate the use of voriconazole as primary prophylaxis of IFD.
Patients and methods

Study population
We performed a prospective, non-comparative, single-cohort study that recruited 59 consecutive pediatric patients with a median age of 9 years (range: 2-17), who were admitted to the hematology ward at the University Hospital Reina Sofia in Co´rdoba, Spain, between October 2004 and July 2010, to receive allo-SCT (regardless of the conditioning regimen or the source of stem cells) for hematological disorders. Patients with a previous history of proven or probable IFD, or anaphylaxis-allergic reactions attributable to azole compounds, were excluded. Before the administration of conditioning regimen, all patients had normal liver function as defined by a liver function test (serum aminotransferases GOT and GPT and bilirubin), which was o3 times the upper limit of normal, and had no clinical evidence of active IFD.
The institutional review board of our center approved this single-institution study. Patients' parents or legally authorized representatives provided written informed consent before the initiation of prophylaxis. In children with prolonged and severe immunosuppression receiving prednisone (40.3 mg/kg) for aGVHD treatment continued antifungal prophylaxis beyond day þ 75 until steroids tapered or until withdrawal. Moreover, children receiving basiliximab or daclizumab for refractory aGVHD also continued antifungal prophylaxis for at least 4 weeks following the last mAb dose. Voriconazole was first administered orally (tablets or solution) or i.v. if oral mucositis or other oral intolerance was present. After discharge, all patients received oral administration. Voriconazole plasma levels were not monitored. The patients' follow-up was 6 months after allo-SCT, and they were included in statistical analysis if they had received at least one dose of study medication.
Study procedures
Study drug withdrawal criteria included occurrence of documented IFD and development of grade 3-4 toxicity according to the updated version of the National Cancer Institute Common Terminology Criteria for Adverse Events.
Study drug discontinuation was applied in patients experiencing toxicity that did not meet the criteria for withdrawal, and were able to resume the study drug if the suspected toxicity resolved within 7 days or was found to be due to another cause. If toxicity corresponding to any scale reappeared after reintroduction, study drug was definitively withdrawn.
Diagnostic procedures included daily physical and analytical examination and a twice-weekly serum galactomannan Ag test. Blood cultures were obtained at the onset of fever, and additional samples were collected if fever persisted. Neutropenic fever was treated according to the published guidelines. 23 Chest radiographs were obtained on enrollment and at the onset of fever, or when symptoms of impaired pulmonary function were observed. When IFD was suspected, an additional serum sample was collected for AGA tests, and a high-resolution computed tomography of the lungs or sinus or an abdominal ultrasound scan was carried out. When possible, the bronchoalveolar lavage fluid was cultured. If the fever persisted for 5 days, despite the use of broad-spectrum antibacterial therapy, voriconazole administration was stopped and empirical antifungal therapy was initiated with i.v. liposomal amphotericin B (3 mg/kg per day) in patients under 14 years of age, or i.v. caspofungin (70 mg the first day and subsequently 50 mg/ day) in patients between 14 and 17 years of age. Preemptive antifungal therapy was started using the same drugs if patients presented as AGA positive or had an image indicating IFD in computed tomography or ultrasound scan.
Definitions IFD was classified as proven or probable according to the definitions from the European Organization for Research, the Treatment of Cancer-Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and the Infectious Diseases Mycoses Study Group. 24 Data were also analyzed according to the revised criteria from these groups. 25 Primary end point was prophylaxis success defined by three criteria: (I) the completion of prophylaxis without the use of antifungal preemptive or empirical therapy, (II) the absence of voriconazole-related clinical or analytical adverse effects resulting in definitive withdrawal and (III) the absence of proven or probable IFD during the 6 months following allo-SCT. Secondary end points included frequency of adverse events, OS at 6 months following stem cell infusion and evaluation of different doses that were used.
Measurement of AGA
The test for galactomannan Ag in the serum was performed twice weekly using AGA EIA (Platelia Aspergillus; BioRad Laboratories, Madrid, Spain). 26 Galactomannan test results were interpreted as positive when an OD index of X0.5 was reached in two consecutive measurements or X0.8 in one sample. 27 
Results
During the study period, 59 children received allo-SCT in our hospital, and three were not recruited to this study because of a previous history of proven or probable fungal infection; however, they received successful secondary prophylaxis with voriconazole. Therefore, a total of 56 children, 32 males and 24 females, were included in this study. The median age was 9 years (range: 2-17). All patients except three received a myeloablative-conditioning regimen. The most common regimens included CY plus TBI, which was administered to 19 patients; and thiotepa, fludarabine and BU, which was also administered to 19 patients. The source of stem cells was from BM for 29 children, mobilized peripheral blood for 7 children and umbilical cord blood for the remaining 20 children. Additional clinical characteristics are summarized in Table 1 .
Prophylaxis success
All 56 patients were evaluated for efficacy and safety (Figure 1) , with a median prophylaxis duration of 81 days (range: 5-214). In this study, 37 children (66.1%) successfully completed primary prophylaxis without empiricalpreemptive antifungal therapy and adverse effects or IFD (Figure 2a) . In 31 patients, voriconazole prophylaxis was stopped on day þ 75, whereas in the remaining 6 it was maintained until a median day of þ 125 (range: 90-214), because of active aGVHD that was treated with immunosuppressive agents. Neutropenic fever developed in 44 children (78.6%). However, the median time to defervescence for the entire group was 3 days (range: 1-18). A total 
Screened for inclusion n=59
Excluded for previous IFD N=3
Assigned to prophylaxis N=56
Successfully completed treatment N=37
Discontinued prophylaxis N=19
Started preemptive treatment N=2
Started empiric treatment N=7
Developed IFD N=1
Withdrawal voriconazole due to adverse effects N=10 Figure 1 Initial disposition and final outcome of children included in this study. of seven patients received empirical antifungal treatment because of persistent fever, one received treatment with caspofungin and six with L-AmB. In addition, two patients received caspofungin (n ¼ 1) or L-AmB (n ¼ 1) as preemptive therapy because of AGA elevation, although no specific radiological findings were detected. In all of these cases, voriconazole was stopped. When we analyzed the prophylaxis success only during the neutropenic period until hematopoietic engraftment, a total of 48 (85.7%) children successfully completed prophylaxis with voriconazole. In eight (14.3%) patients, voriconazole was withdrawn during neutropenic period because of initiation of preemptive (n ¼ 1) or empirical (n ¼ 4) antifungal therapy with L-AmB or because of the presence of adverse effects (n ¼ 3).
Only one patient (1.8%, confidence interval 95% 0-9.9%) developed probable IFD. Excluding 10 patients who withdrew voriconazole prophylaxis because of adverse events, IFD incidence is 2.17% (confidence interval 95%, 0-12.1%). He was a 16-year-old patient who underwent an unrelated non-identical HLA cord blood transplantation for acute lymphoblastic leukemia after the first CR. This patient received a prolonged course of prednisone to treat intestinal grade 3 aGVHD, and developed CMV infection that was treated with oral valganciclovir. He was admitted to the hospital on day þ 130 for progression of aGVHD. On day þ 135, voriconazole treatment was stopped because of a prolonged fever and caspofungin was started. AGA was highly positive and the computed tomography showed lesions that were highly compatible with invasive pulmonary aspergillosis. He died on day þ 151 despite combined antifungal therapy with caspofungin and L-AmB. No other patients undergoing voriconazole prophylaxis were diagnosed with proven or probable IFD according to applied 2002 European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria or even revised according to updated 2008 criteria. 25 
Adverse effects
The safety profile of voriconazole was evaluated in all patients who received at least one dose of voriconazole. In 10 (17.8%) children, adverse effects related to voriconazole prophylaxis were detected, forcing definitive withdrawal. Nevertheless, in these cases, the median length of voriconazole prophylaxis was 26.5 days (range: 5-127; see Table 2 ). Only three patients stopped prophylaxis in the early post-transplant period before granulocytic recovery. The most frequent adverse effect due to azole treatment was persistent hepatic damage with elevated cytolytic enzymes that were 45 times (grade 3) the basal levels in four patients, and grades 1-2 that reappeared again when drug was resumed leading to definitive withdraw in three children. Skin rash (grade 3, N ¼ 1), pancreatitis (N ¼ 1) and tremor (grade 3, N ¼ 1) were also observed. All adverse effects were resolved once voriconazole administration was stopped. We did not observe any other side effects with voriconazole use, such as visual disturbances or renal impairment, related to the i.v. formulation.
In addition, hepatic veno-occlusive disease occurred in two patients, which forced a transient discontinuation of prophylaxis. Voriconazole was safely reintroduced after veno-occlusive disease was resolved. In other three patients, voriconazole was temporarily stopped for 3-7 days because of a slight elevation of liver enzymes (less than five times basal levels) and was uneventfully reintroduced.
OS
The OS at 180 days was 85.7 ± 4.7% (Figure 2b) . Eight children died during this period and only one death was due to IFD. Other causes of death during the first 6 months after allo-SCT included leukemia relapse (N ¼ 2), CMV infection (N ¼ 2; pulmonary and intestinal), bacterial sepsis due to Escherichia coli (N ¼ 1), hepatic aGVHD grade 4 (N ¼ 1) and sudden death (N ¼ 1) in a patient who was previously diagnosed with Tetralogy of Fallot. In our series, median time follow-up was 27.75 months and the OS was 69±7%.
Voriconazole doses
The voriconazole dose was modified according to current the pharmacological guidelines, and was increased from 5 mg/kg per 12 h (N ¼ 23) to 7 mg/kg per 12 h (N ¼ 33) in February 2007. There was no statistical difference between groups when comparing efficacy (successful completion of treatment, initiation of empiric or preemptive treatment or IFD) or safety (adverse effects). Additional data are detailed in Table 3 . 
Discussion
To the best of our knowledge, this is the first pediatric prospective non-comparative clinical trial of an antifungal prophylaxis, with allo-SCT, using voriconazole. On the basis of the results of our study, voriconazole appears to be effective in preventing IFD in these high-risk patients with easily manageable adverse events in most instances. In this study, a total of 37 (66.1%) patients successfully completed prophylaxis and only one of the enrolled patients developed a probable IFD. Dvorak et al. 5 showed that most IFD in children who received an allo-SCT was diagnosed in the first month after stem cells infusion. In this sense, our results focused in the neutropenic phase, showed no patient diagnosed with IFD and 48 (85.7%) children successfully complete the prophylaxis without empirical-preemptive antifungal therapy or adverse effects. These results are clearly superior to those previously reported by Dvorak et al. 5 and van Burik et al. 19 using low-dose amphotericin B deoxycholate/fluconazole and micafungine/fluconazole, respectively, in the neutropenic period.
For years, fluconazole has been the gold standard drug for prophylaxis in hematological patients undergoing aggressive chemotherapy or SCT. 28 In our center, from January 2000 to October 2004, the incidence of IFD in pediatric patients who underwent allo-SCT was 12.1% (4 IFD in 33 pediatric allo-SCT). The discovery of new antifungal agents in the last decade has changed the way we understand antifungal prophylaxis in high-risk patients. Therefore, many centers have conducted additional prophylaxis trials aiming to reduce the incidence and mortality of IFD, 13, [16] [17] [18] but children are frequently excluded because of the lack of an appropriately characterized or unknown dosage. In our experience, voriconazole is effective as a primary prophylactic agent and is an improvement over previously published results using low-dose amphotericin B deoxycholate/fluconazole (13% IFD) 5 or L-AmB (9.7% of 51 patients underwent 57 allo-SCT had an IFD, whereas none developed an invasive mold infection), 22 which are similar to the results of Kolve et al. 29 who used L-AmB as primary or secondary prophylaxis in children (3.5% IFD in the global series), and van Burik et al. 19 who used micafungin only during neutropenic phase (2.5% of IFD). In contrast to the published experience of Trifilio et al., 30 who observed breakthrough fungal infections due to opportunistic molds or yeast, in a retrospective study that also included children, we did not observe any of these results.
One advantage of using voriconazole in the pediatric population is the availability of both oral (particularly solution) and i.v. formulations. I.v. delivery allows patients with difficulty in swallowing, due to severe mucositis or impaired intestinal absorption, to receive prophylaxis, which is not possible with posaconazole. Following discharge from the hospital, children can maintain prophylaxis with an oral formulation, which is easily administered to infants and children who are frequently reluctant to ingest tablets.
In our study, the majority of adverse effects developed after hematopoietic engraftment and neutrophil recovery had occurred. Remarkably, there were no life-threatening adverse effects, and all were resolved once voriconazole administration was stopped. The most frequent complication was the elevation of cytolytic hepatic enzymes, but a comparable percentage of patients who were given voriconazole in another study also definitively withdrew because of hepatic toxicity, as reported by Amigues et al. 31 Notably, there were no statistical differences between doses of 5 and 7 mg/kg per 12 h in prophylaxis efficacy nor safety. This is important because a dose of 7 mg/kg per 12 h is more likely to reach adequate plasma levels, and at this level loading doses or individual dosage adjustments are not considered necessary when administering voriconazole to children. 32 With regard to drug interactions, it is important to note that voriconazole increases blood levels of CsA, 33 which requires drug adjustment and closer monitoring.
The primary drawback of our study is that a prospective control group is lacking. Currently, most authors recommend a mold-active agent as prophylaxis, 34 although recently, a double-blind trial comparing voriconazole and fluconazole with promising results was published. 20 Pediatric patients were included, and there was a trend toward fewer IFDs and less-frequent initiation of empirical antifungal therapy in the voriconazole arm. Unfortunately, children (n ¼ 27 and n ¼ 24 in the voriconazole and fluconazole arms, respectively) were not analyzed separately from the global series. In conclusion, this is a prospective large study with a homogeneous group of pediatric patients and a 6-month extended follow-up. Our results suggest that voriconazole can safely and effectively be used as antifungal prophylaxis in pediatric populations, although comparative studies are necessary to confirm these promising results.
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